The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial)

MLA

Ping Chen, et al. “The Efficacy and Safety of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).” COPD, vol. 15, no. 4, Sept. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d6391854a2e38247662fbe8b1247464f&authtype=sso&custid=ns315887.

APA

Ping Chen, Aik Han Goh, Haoyan Wang, Yijiang Huang, Limin Wang, Changzheng Wang, Li Zhao, Nanshan Zhong, Jinping Zheng, Linda Luo, David A. Lipson, Xin Du, & Fuxin Hui. (2018). The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial). COPD, 15(4).

Chicago

Ping Chen, Aik Han Goh, Haoyan Wang, Yijiang Huang, Limin Wang, Changzheng Wang, Li Zhao, et al. 2018. “The Efficacy and Safety of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).” COPD 15 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d6391854a2e38247662fbe8b1247464f&authtype=sso&custid=ns315887.